Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Jon Godwin

Research output: Contribution to journalArticle

Abstract

Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention. We undertook meta-analyses of serious vascular events (myocardial infarction, stroke, or vascular death) and major bleeds in six primary prevention trials (95 000 individuals at low average risk, 660 000 person-years, 3554 serious vascular events) and 16 secondary prevention trials (17 000 individuals at high average risk, 43 000 person-years, 3306 serious vascular events) that compared long-term aspirin versus control. We report intention-to-treat analyses of first events during the scheduled treatment period. Jon Godwin is a member of the ATT Collaboration, the group author of this article.

Original languageEnglish
Pages (from-to)1849-1860
Number of pages12
JournalLancet
Volume373
Issue number9678
DOIs
Publication statusPublished - 1 May 2009

Keywords

  • aspirin
  • vascular disease
  • clinical trials

Fingerprint Dive into the research topics of 'Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials'. Together they form a unique fingerprint.

  • Cite this